KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Total Current Liabilities (2019 - 2025)

Historic Total Current Liabilities for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $530.8 million.

  • Royalty Pharma's Total Current Liabilities fell 5454.52% to $530.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $530.8 million, marking a year-over-year decrease of 5454.52%. This contributed to the annual value of $1.3 billion for FY2024, which is 67682.45% up from last year.
  • Latest data reveals that Royalty Pharma reported Total Current Liabilities of $530.8 million as of Q3 2025, which was down 5454.52% from $1.2 billion recorded in Q2 2025.
  • Royalty Pharma's Total Current Liabilities' 5-year high stood at $1.3 billion during Q4 2024, with a 5-year trough of $124.6 million in Q1 2024.
  • In the last 5 years, Royalty Pharma's Total Current Liabilities had a median value of $284.0 million in 2021 and averaged $626.5 million.
  • As far as peak fluctuations go, Royalty Pharma's Total Current Liabilities plummeted by 8884.62% in 2024, and later skyrocketed by 84951.76% in 2025.
  • Quarter analysis of 5 years shows Royalty Pharma's Total Current Liabilities stood at $171.2 million in 2021, then surged by 581.33% to $1.2 billion in 2022, then plummeted by 86.17% to $161.4 million in 2023, then soared by 676.82% to $1.3 billion in 2024, then plummeted by 57.66% to $530.8 million in 2025.
  • Its Total Current Liabilities stands at $530.8 million for Q3 2025, versus $1.2 billion for Q2 2025 and $1.2 billion for Q1 2025.